Suppliers / Rohto Mentholatum Vietnam

Rohto Mentholatum Vietnam

United Arab Emirates Updated 9 July 2026

Rohto Mentholatum Vietnam is a finished-dose manufacturer based in United Arab Emirates. It appears in 24 regulatory filings across 4 regulators, without an active US DMF or CEP on file. Its filings concentrate with DAV (Vietnam), EDE (AE) and NPRA (MY). Its most recent recorded inspection, by US FDA, closed on 1 November 2019 as VAI.

0
active US DMFs
0
valid CEPs
2
registered plants 1 with an FDA FEI number
24
filings across 4 regulators
These figures were checked against the regulators' own files on 25 July 2026
Plants
1 of 1 confirmed
Inspections
4 of 4 confirmed
Sources: FDA Establishment Registration, read 4 May 2026. FDA drug inspection classifications, read 4 May 2026.

Inspection history

  • 1 November 2019 VAI US FDA
  • 16 March 2018 VAI US FDA
  • 14 April 2015 VAI US FDA
  • 15 May 2012 OAI US FDA

NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.

Registered plants

Site FDA FEI
BINH DUONG, United Arab Emirates Not on file
Vietnam, Vietnam 3008808745

Filings and GMP by regulator

Regulator Filings GMP certificates
DAV (Vietnam) 12 None
EDE (AE) 6 None
NPRA (MY) 3 None
UZPHARM (UZ) 3 None

Comparing suppliers?

Choose your molecules and target markets. Rohto Mentholatum Vietnam comes back tiered against every other supplier able to file there.

Start for free
No sales call.

Open risk flags

  • The most recent inspection outcome was VAI, on 1 November 2019.

Sources on this page

FDA
Drug master files, establishment registration, inspection classifications
EDQM
Certificates of suitability